Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 47 от 222

Recruiting Phase 1/2

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Начало: 13.01.2026 Край: 02.08.2032 Възраст: от 18 г. Treatment

Australia, China, France +8 Novartis Pharmaceuticals NCT07190300

Recruiting

A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)

Food Allergies Peanut Allergies Egg Allergy Milk Allergy

The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy. It aims to: • Compare long-term changes in health-related quality of life (HRQL) at 5-15 years after stopping OIT in participants who achieved remission and those who did not. Participants will attend a single follow-up visit for: * A blood test * Skin prick test (SPT) * Allergy questionnaires

Начало: 13.01.2026 Край: 01.01.2027

Australia Murdoch Childrens Research Institute NCT07359183

Recruiting

Terraflora Daily Care and Gastrointestinal Health

Gastrointestinal

A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.

Начало: 12.01.2026 Край: 01.09.2026 Възраст: от 25 г.

United States OvationLab NCT07355634

Recruiting Phase 3

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Diabetes Mellitus, Type 1

The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.

Начало: 12.01.2026 Край: 01.07.2031 Възраст: 1–35 г. Treatment

Australia, Belgium, Brazil +14 Eli Lilly and Company NCT07222137

Recruiting Phase 1

Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies

Type 1 Interferonopathies

Open-Label Study (Phase Ib) of Type 1 Interferonopathy patients receiving IMSB301 monotherapy.

Начало: 12.01.2026 Край: 30.07.2026 Възраст: от 12 г. Treatment

Australia ImmuneSensor Therapeutics Inc. NCT07364513

Recruiting Phase 1

Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis

ALS (Amyotrophic Lateral Sclerosis)

This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.

Начало: 12.01.2026 Край: 01.12.2030 Възраст: 18–80 г. Treatment

Australia Celosia Therapeutics Pty Ltd NCT07401121

Recruiting

Nigella Sativa Oil for Eczematous Otitis Externa

Eczema/Atopic Dermatitis Otitis Externa

Eczematous otitis externa is a common inflammatory condition of the external auditory canal characterized by itching, discomfort, discharge, and pain. Topical corticosteroids are widely used for treatment; however, alternative therapies with fewer side effects are of increasing interest. This study aims to compare the efficacy of Nigella sativa (black seed) oil and mometasone furoate ear drops in the treatment of eczematous otitis externa. Nigella sativa is a natural product with known anti-inflammatory and antimicrobial properties. In this randomized, controlled clinical trial, adult patients with eczematous otitis externa will be assigned to receive either Nigella sativa oil or mometasone furoate ear drops for 10 days. Clinical symptoms and inflammatory findings will be evaluated at baseline and after treatment. The objective of this study is to determine whether Nigella sativa oil is an effective and safe alternative to topical corticosteroid therapy.

Начало: 12.01.2026 Край: 01.07.2026 Възраст: от 18 г.

Turkey (Türkiye) Bezmialem Vakif University NCT07525505

Recruiting Phase 1/2

A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

This clinical trial is an open-label, single-arm, non-randomized, dose-escalation and dose-expansion study targeting subjects with unresectable, advanced, malignant solid tumors who have failed or are unsuitable for standard treatments or refused the existing treatments. This study is divided into a dose-escalation phase (Phase I) and a dose-expansion phase (Phase II). Phase I (dose escalation) is designed to preliminarily evaluate the safety and tolerability of VIB305 in advanced solid tumors, to determine the nature and incidence of dose-limiting toxicities (DLTs), and thereby to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Based on the findings from the Phase I portion for evaluation in the Phase II portion. Phase II (dose expansion) will enroll additional cohorts to further assess the safety and tolerability, PK profile, preliminary antitumor activity and immunogenicity of VIB305 in specific tumor types (selected based on all available data).

Начало: 12.01.2026 Край: 30.06.2027 Възраст: от 18 г. Treatment

Australia, China Vibrant Sciences Limited NCT07222969

Recruiting Phase 1

A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults

Healthy Participants Healthy Adult Females Healthy Adult Male Healthy +1

This is a double-blind, randomized, placebo-controlled, single ascending dose (SAD) study to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of DF5112 in healthy adult participants. A total of 48 participants are planned to be randomized into 6 cohorts. Additional cohorts at intermediate dose levels may be evaluated. Each cohort will include 8 healthy participants randomized to receive DF5112 or placebo through intravenous (IV) or subcutaneous (SC) administration. Following dose administration participants will be confined at the clinical research unit for observation for approximately 1 week and then will return for subsequent pre-identified follow up visits through Day 29.

Начало: 12.01.2026 Край: 01.12.2026 Възраст: 18–55 г. Other

Australia Dragonfly Therapeutics NCT07232121

Recruiting Phase 3

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis.

Plaque Psoriasis

This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.

Начало: 12.01.2026 Край: 03.12.2027 Възраст: 18–70 г.

China InventisBio Co., Ltd NCT07326813

Recruiting

Fucoidan in the Treatment of Active Rheumatoid Arthritis

Arthritis, Rheumatoid

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint destruction and autoantibody production. Scavenger receptor-A (SR-A), a pattern recognition receptor primarily expressed on myeloid-derived cells, is significantly elevated in the serum of RA patients. Genetic knockout of SR-A completely protects mice from collagen-induced arthritis (CIA). As an SR-A inhibitor, fucoidan markedly suppresses the progression of CIA in mice. Given the potential role of SR-A in RA pathogenesis, the investigators hypothesize that fucoidan may exert therapeutic effects in RA by specifically targeting human SR-A. This study aims to investigate the efficacy of fucoidan in RA treatment through a multicenter, single-arm, open-label trial, providing original insights into its clinical application. The investigators plan to enroll 40 patients with a 12-week follow-up period. Clinical manifestations, laboratory parameters, and disease activity will be systematically evaluated to assess therapeutic outcomes. The findings will provide evidence-based medical data for RA treatment strategies.

Начало: 10.01.2026 Край: 01.07.2027 Възраст: 18–65 г.

China Peking University People's Hospital NCT07045896

Recruiting Phase 1

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

Metabolic Dysfunction-Associated Steatohepatitis

This is a Phase I, open-label, randomized, single-dose, 2-part study designed to evaluate the food effect and relative bioavailability of ECC4703 in healthy adult participants.

Начало: 10.01.2026 Край: 01.05.2026 Възраст: 18–65 г. Treatment

Australia Eccogene NCT07334080

Recruiting Phase 3

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Hyperphosphatemia Patients on Hemodialysis

A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Начало: 09.01.2026 Край: 29.12.2026 Възраст: от 18 г.

Japan Taisho Pharmaceutical Co., Ltd. NCT07285291

Recruiting Phase 1

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \

Начало: 09.01.2026 Край: 31.03.2030 Възраст: 18–79 г.

United States Insmed Gene Therapy LLC NCT07290062

Recruiting Phase 2

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

Asthma

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.

Начало: 09.01.2026 Край: 01.01.2027 Възраст: 18–75 г.

United States Enveda Therapeutics NCT07301255

Recruiting Phase 1

A Study of AZD0120 in Autoimmune Diseases

Systemic Sclerosis Idiopathic Inflammatory Myopathies Rheumatoid Arthritis

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Начало: 09.01.2026 Край: 22.02.2028 Възраст: 18–75 г. Treatment

Australia, Germany, Spain +2 AstraZeneca NCT07295847

Recruiting

Adult Disease Risk Prediction Using Wearables, Hearing, and Health Data

Chronic Disease Risk Assessment

This prospective cohort study aims to develop and validate a personalized disease risk prediction model for adults by integrating multiple sources of health data. The study will recruit community-dwelling adults aged 18 years and older in Taiwan. After providing informed consent, participants will complete a structured questionnaire, undergo pure tone hearing testing, and wear a smartwatch for 2 weeks to collect continuous physiological data, including heart rate and physical activity. With participant authorization, the study will also collect data from personal health records and national health insurance databases to allow longer-term follow-up of health outcomes. The main goals of the study are to examine the relationships among hearing, lifestyle factors, and wearable device data; to identify combinations of risk factors associated with progression from health to subclinical or chronic disease states; and to develop analytical methods for integrating heterogeneous health data from questionnaires, physiological monitoring, hearing tests, and medical databases. Machine learning methods will be used to identify important predictors and build risk prediction models. The study hypothesis is that combining hearing measures, lifestyle information, wearable physiological data, and longitudinal medical record data will improve the ability to identify individuals at higher risk of future disease compared with using a single source of information alone. The long-term objective is to support early risk identification, personalized health management, and prevention strategies in community adults.

Начало: 09.01.2026 Край: 01.01.2029 Възраст: от 18 г.

Taiwan National Health Research Institutes, Taiwan NCT07541547

Recruiting Phase 1/2

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Acute Lymphoblastic Leukaemia Acute Myeloid Leukaemia Higher-risk Myelodysplastic Syndromes

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.

Начало: 09.01.2026 Край: 15.02.2029 Възраст: от 16 г. Treatment

Australia, Canada, Denmark +6 AstraZeneca NCT07155226

Recruiting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Transthyretin Amyloidosis With Cardiomyopathy

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Начало: 09.01.2026 Край: 23.10.2030 Възраст: от 18 г.

United States Alnylam Pharmaceuticals NCT07358078

Recruiting Phase 1

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Solid Tumors Hematologic Malignancies

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Начало: 08.01.2026 Край: 18.08.2028 Възраст: от 18 г. Treatment

Australia, Belgium, Denmark +2 Incyte Corporation NCT07195916

1 … 45 46 47 48 49 … 222